SCHEMBL923902

SCHEMBL923902

CC(=O)Nc1ccc(NN=C2C(N)=NN=C2N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NOX1 Q9Y5S8 1/20 0.47
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
BRD4 O60885 1/20 0.46
NR1I2 O75469 1/20 0.46
MB P02144 1/20 0.46
CYP1A1 P04798 1/20 0.46
CA3 P07451 1/20 0.46
CYP3A4 P08684 1/20 0.46
RARG P13631 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL921617 0.84 NOX1 (0.49) SMN1; SMN2HTTL3MBTL1NOX1KMT2A
SCHEMBL921618 0.84 NOX1 (0.49) SMN1; SMN2HTTL3MBTL1NOX1KMT2A
SCHEMBL922373 0.74 ALDH1A1 (0.44) SMN1; SMN2HTTKMT2AMAPTMEN1
SCHEMBL923317 0.74 EIF2AK2 (0.40) SMN1; SMN2KMT2ACA12CA1CA2
SCHEMBL921999 0.74 ALDH1A1 (0.46) L3MBTL1KMT2AMAPTMEN1CA1
SCHEMBL922522 0.73 ROCK1 (0.40) SMN1; SMN2HTTNOX1KMT2AMAPT
SCHEMBL924770 0.73 NR4A1 (0.46) SMN1; SMN2HTTL3MBTL1KMT2AMAPT
SCHEMBL922071 0.73 DEPTOR (0.53) SMN1; SMN2HTTL3MBTL1NOX1KMT2A
SCHEMBL924261 0.72 SMN1; SMN2 (0.43) SMN1; SMN2HTTKMT2AMEN1CA12
SCHEMBL861674 0.72 SMN1; SMN2 (0.84) SMN1; SMN2HTTL3MBTL1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6214813-B1 AZOPYRAZOLES KINETEK PHARMACEUTICALS, INC. (CA) 2001-04-10 US claimed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed
EP-1276723-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY Kinetek Pharmaceuticals, Inc. (CA) 2003-01-22 EP disclosed
US-6436915-B1 ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS KINETEK PHARMACEUTICALS, INC. (CA) 2002-08-20 US disclosed
US-20020042501-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2002-04-11 US disclosed
WO-2001077080-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY KINETEK PHARMACEUTICALS, INC. (CA) 2001-10-18 WO disclosed
US-6214813-B1 AZOPYRAZOLES KINETEK PHARMACEUTICALS, INC. (CA) 2001-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 SMN1; SMN2 4161/4885HTT 1145/4885L3MBTL1 1249/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 SMN1; SMN2 4161/4885HTT 1145/4885L3MBTL1 1249/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC SMN1; SMN2 2243/4885HTT 1642/4885L3MBTL1 1450/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C SMN1; SMN2 3557/4885HTT 2491/4885L3MBTL1 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.